1. Dang CV. 2012. MYC on the path to cancer. Cell 149:22-35.
2. Liu J, Perumal NB, Oldfield CJ, Su EW, Uversky VN, Dunker AK. 2006. Intrinsic disorder in transcription factors. Biochemistry 45:6873-6888.
3. Tsafou K, Tiwari PB, Forman-Kay JD, Metallo SJ, Toretsky JA. 2018. Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm. J Mol Biol 430:2321-2341.
4. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. 1998. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17:2463-2472.
5. Beaulieu ME, Jauset T, Masso-Valles D, Martinez-Martin S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sanchez-Hervas M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martin G, Letourneau D, Montagne M, Morcillo Alonso MA, Whitfield JR, Lavigne P, Soucek L. 2019. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med 11.
6. Donati B, Lorenzini E, Ciarrocchi A. 2018. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer 17:164.
7. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. 2014. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 33:2928-2937.
8. Poole CJ, van Riggelen J. 2017. MYC-Master Regulator of the Cancer Epigenome and Transcriptome. Genes (Basel) 8.
9. Muhar M, Ebert A, Neumann T, Umkehrer C, Jude J, Wieshofer C, Rescheneder P, Lipp JJ, Herzog VA, Reichholf B, Cisneros DA, Hoffmann T, Schlapansky MF, Bhat P, von Haeseler A, Kocher T, Obenauf AC, Popow J, Ameres SL, Zuber J. 2018. SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science 360:800-805.
10. Jones PA, Issa JP, Baylin S. 2016. Targeting the cancer epigenome for therapy. Nat Rev Genet 17:630-641.
11. Shi J, Vakoc CR. 2014. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 54:728-736.
12. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. 2010. Selective inhibition of BET bromodomains. Nature 468:1067-1073.
13. Ghurye RR, Stewart HJ, Chevassut TJ. 2015. Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells. Cytokine 71:415-417.
14. Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, Bair S, Newton G, Lichtman AH, Kung AL, Yang T, Wang H, Luscinskas FW, Croce KJ, Bradner JE, Plutzky J. 2014. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 56:219-231.
15. Chen J, Wang Z, Hu X, Chen R, Romero-Gallo J, Peek RM, Jr., Chen LF. 2016. BET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation. J Immunol 196:4132-4142.
16. Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS. 2016. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-1286.
17. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
18. Schalling M, Ekman M, Kaaya EE, Linde A, Biberfeld P. 1995. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med 1:707-708.
19. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191.
20. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88:645-656.
21. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
22. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F. 2000. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 96:2069-2073.
23. Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R. 2010. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 51:350-358.
24. Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R. 2013. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 122:4189-4198.
25. Ganem D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 120:939-949.
26. Mesri EA, Cesarman E, Boshoff C. 2010. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10:707-719.
27. Lukac DM, Renne R, Kirshner JR, Ganem D. 1998. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252:304-312.
28. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G. 1998. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 95:10866-10871.
29. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. 2003. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol 77:4205-4220.
30. Lukac DM, Kirshner JR, Ganem D. 1999. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 73:9348-9361.
31. Xu Y, AuCoin DP, Huete AR, Cei SA, Hanson LJ, Pari GS. 2005. A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J Virol 79:3479-3487.
32. Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, Miller G. 1999. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73:2232-2242.
33. Guito J, Lukac DM. 2012. KSHV Rta Promoter Specification and Viral Reactivation. Front Microbiol 3:30.
34. Izumiya Y, Lin SF, Ellison TJ, Levy AM, Mayeur GL, Izumiya C, Kung HJ. 2003. Cell cycle regulation by Kaposi's sarcoma-associated herpesvirus K-bZIP: direct interaction with cyclin-CDK2 and induction of G1 growth arrest. J Virol 77:9652-9661.
35. Wu FY, Tang QQ, Chen H, ApRhys C, Farrell C, Chen J, Fujimuro M, Lane MD, Hayward GS. 2002. Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha. Proc Natl Acad Sci U S A 99:10683-10688.
36. Chen CP, Lyu Y, Chuang F, Nakano K, Izumiya C, Jin D, Campbell M, Izumiya Y. 2017. Kaposi's Sarcoma-Associated Herpesvirus Hijacks RNA Polymerase II To Create a Viral Transcriptional Factory. J Virol 91.
37. Wei X, Bai L, Dong L, Liu H, Xing P, Zhou Z, Wu S, Lan K. 2019. NCOA2 promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus by enhancing the expression of the master switch protein RTA. PLoS Pathog 15:e1008160.
38. Gwack Y, Baek HJ, Nakamura H, Lee SH, Meisterernst M, Roeder RG, Jung JU. 2003. Principal role of TRAP/mediator and SWI/SNF complexes in Kaposi's sarcoma-associated herpesvirus RTA-mediated lytic reactivation. Mol Cell Biol 23:2055-2067.
39. Iida S, Mine S, Ueda K, Suzuki T, Hasegawa H, Katano H. 2020. Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells. J Virol doi:10.1128/JVI.01785-20.
40. Mohammed H, D'Santos C, Serandour AA, Ali HR, Brown GD, Atkins A, Rueda OM, Holmes KA, Theodorou V, Robinson JL, Zwart W, Saadi A, Ross-Innes CS, Chin SF, Menon S, Stingl J, Palmieri C, Caldas C, Carroll JS. 2013. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep 3:342-349.
41. Cruickshank VA, Sroczynska P, Sankar A, Miyagi S, Rundsten CF, Johansen JV, Helin K. 2015. SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance. PLoS One 10:e0142806.
42. Toth Z, Brulois KF, Wong LY, Lee HR, Chung B, Jung JU. 2012. Negative elongation factor-mediated suppression of RNA polymerase II elongation of Kaposi's sarcoma-associated herpesvirus lytic gene expression. J Virol 86:9696-9707.
43. Meszaros B, Erdos G, Dosztanyi Z. 2018. IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding. Nucleic Acids Res 46:W329-W337.
44. Erdos G, Dosztanyi Z. 2020. Analyzing Protein Disorder with IUPred2A. Curr Protoc Bioinformatics 70:e99.
45. Ravarani CN, Erkina TY, De Baets G, Dudman DC, Erkine AM, Babu MM. 2018. High-throughput discovery of functional disordered regions: investigation of transactivation domains. Mol Syst Biol 14:e8190.
46. Zou L, Peng Q, Wang P, Zhou B. 2017. Progress in Research and Application of HIV-1 TAT-Derived Cell-Penetrating Peptide. J Membr Biol 250:115-122.
47. Tugyi R, Uray K, Ivan D, Fellinger E, Perkins A, Hudecz F. 2005. Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A 102:413-418.
48. Herzog VA, Reichholf B, Neumann T, Rescheneder P, Bhat P, Burkard TR, Wlotzka W, von Haeseler A, Zuber J, Ameres SL. 2017. Thiol-linked alkylation of RNA to assess expression dynamics. Nat Methods 14:1198-1204.
49. Anonymous. !!! INVALID CITATION !!! (9).
50. Zhou F, Shimoda M, Olney L, Lyu Y, Tran K, Jiang G, Nakano K, Davis RR, Tepper CG, Maverakis E, Campbell M, Li Y, Dandekar S, Izumiya Y. 2017. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. Mol Cancer Ther 16:2627-2638.
51. Zambelli F, Prazzoli GM, Pesole G, Pavesi G. 2012. Cscan: finding common regulators of a set of genes by using a collection of genome-wide ChIP-seq datasets. Nucleic Acids Res 40:W510-515.
52. Gopalakrishnan R, Matta H, Tolani B, Triche T, Jr., Chaudhary PM. 2016. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35:1797-1810.
53. Manzano M, Gunther T, Ju H, Nicholas J, Bartom ET, Grundhoff A, Gottwein E. 2020. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma. mBio 11.
54. Wang C, Zhang L, Ke L, Ding W, Jiang S, Li D, Narita Y, Hou I, Liang J, Li S, Xiao H, Gottwein E, Kaye KM, Teng M, Zhao B. 2020. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. Nat Commun 11:6318.
55. Park A, Oh S, Jung KL, Choi UY, Lee HR, Rosenfeld MG, Jung JU. 2020. Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional MYC superenhancers and enhancer RNAs. Proc Natl Acad Sci U S A 117:21618-21627.
56. Dai L, Trillo-Tinoco J, Bai L, Kang B, Xu Z, Wen X, Del Valle L, Qin Z. 2014. Systematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL). PLoS One 9:e90349.
57. Zhong W, Mao S, Tobis S, Angelis E, Jordan MC, Roos KP, Fishbein MC, de Alboran IM, MacLellan WR. 2006. Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. EMBO J 25:3869-3879.
58. Zanet J, Pibre S, Jacquet C, Ramirez A, de Alboran IM, Gandarillas A. 2005. Endogenous Myc controls mammalian epidermal cell size, hyperproliferation, endoreplication and stem cell amplification. J Cell Sci 118:1693-1704.
59. Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Goncalves PH, Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, Uldrick TS. 2019. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood 133:1753-1761.
60. Wang S, Liu S, Wu M, Geng Y, Wood C. 2001. Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 ORF50 gene product contains a potent C-terminal activation domain which activates gene expression via a specific target sequence. Arch Virol 146:1415-1426.
61. Izumiya Y, Izumiya C, Hsia D, Ellison TJ, Luciw PA, Kung HJ. 2009. NF-kappaB serves as a cellular sensor of Kaposi's sarcoma-associated herpesvirus latency and negatively regulates K-Rta by antagonizing the RBP-Jkappa coactivator. J Virol 83:4435-4446.
62. Yu Y, Wang SE, Hayward GS. 2005. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22:59-70.
63. Yu Y, Hayward GS. 2010. The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 33:863-877.
64. Lee HR, Doganay S, Chung B, Toth Z, Brulois K, Lee S, Kanketayeva Z, Feng P, Ha T, Jung JU. 2014. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication. J Virol 88:2183-2194.
65. Li X, Chen S, Feng J, Deng H, Sun R. 2010. Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency. J Virol 84:8945-8948.
66. Forero A, McCormick KD, Jenkins FJ, Sarkar SN. 2014. Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells. Virology 458-459:4-10.
67. Guo R, Jiang C, Zhang Y, Govande A, Trudeau SJ, Chen F, Fry CJ, Puri R, Wolinsky E, Schineller M, Frost TC, Gebre M, Zhao B, Giulino-Roth L, Doench JG, Teng M, Gewurz BE. 2020. MYC Controls the Epstein-Barr Virus Lytic Switch. Mol Cell 78:653-669 e658.
68. Bu W, Carroll KD, Palmeri D, Lukac DM. 2007. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer. J Virol 81:5788-5806.
69. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455:679-683.
70. Mittal P, Roberts CWM. 2020. The SWI/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol 17:435-448.
71. Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM. 2020. Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. Trends Genet 36:936-950.
72. Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, Andersson AC, Lindstedt P, Stenvang J, Gullberg M, Fredriksson S. 2014. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9:e95192.
73. Skene PJ, Henikoff S. 2017. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. Elife 6.
74. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357-359.
75. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS. 2008. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9:R137.
76. Freese NH, Norris DC, Loraine AE. 2016. Integrated genome browser: visual analytics platform for genomics. Bioinformatics 32:2089-2095.
77. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. 2017. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14:417-419.
78. Soneson C, Love MI, Robinson MD. 2015. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4:1521.
79. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550.
80. Neumann T, Herzog VA, Muhar M, von Haeseler A, Zuber J, Ameres SL, Rescheneder P. 2019. Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets. BMC Bioinformatics 20:258.
81. Sedlazeck FJ, Rescheneder P, von Haeseler A. 2013. NextGenMap: fast and accurate read mapping in highly polymorphic genomes. Bioinformatics 29:2790-2791.
82. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. 2012. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22:568-576.
83. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550.
84. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273.
85. Kim KY, Huerta SB, Izumiya C, Wang DH, Martinez A, Shevchenko B, Kung HJ, Campbell M, Izumiya Y. 2013. Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. J Virol 87:6782-6793.
86. Levy AM, Gilad O, Xia L, Izumiya Y, Choi J, Tsalenko A, Yakhini Z, Witter R, Lee L, Cardona CJ, Kung HJ. 2005. Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: a converging transforming pathway for avian oncoviruses. Proc Natl Acad Sci U S A 102:14831-14836.